Akademik Veri Yönetim Sistemi
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.30, sa.2, ss.103-109, 2020 (SCI-Expanded)
The prognosis of melanoma is extremely poor. There are no biomarker that indicate the prognosis. The indirect markers of the antitumoral response such as the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), derived NLR (dNLR), absolute neutrophil count (ANC), absolute lymphocyte count (ALC) etc. have recently begun to be emphasized. Increased NLR, PLR and dNLR as a consequence of chronic inflammation have been found to be associated with poor prognosis in many cancers. The aim of this study is explore the role of this parameters in patients with early-stage melanoma. We retrospectively evaluated 120 patients admitted to our clinic with stage I-Ill melanoma with ANC, ALC, absolute platelet count(APC), as well as NLR, dNLR, and PLR values at the time of diagnosis, relaps and metastasis and evaluate their impact on prognosis. Patients with active infection, receiving steroids, with a chronic inflammatory disease that may alter the hematological parameters, and those with another malignancy other than melanoma were excluded. The median follow-up was 52 months. OS and DFS were significantly worse in patients with an NLR above 2.84. Also, in patients with a dNLR value above 1.96 (p= 0.007). The were no relationship between PLR value, OS and DFS, and between gender and OS. OS was significantly lower in patients over 65 years of age (p< 0.001). These results suggested that haematological parameters can be used to estimate the prognosis of melanoma. These results suggested that haematological parameters can be used to estimate the prognosis of melanoma.